Albert Bourla, Pfizer CEO (AP Images)

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out deals

One of the icon­ic brands in bio­phar­ma, Pfiz­er took a big gam­ble on the strength of its in-house sci­ence when it de­cid­ed to of­fload its flag­ging Up­john gener­ics busi­ness last year. Now, a more ag­ile Pfiz­er is look­ing to ce­ment its iden­ti­ty for the fu­ture, but one thing will stay the same: M&A is still very much a part of the game plan.

With its Up­john gener­ics busi­ness off the books, Pfiz­er is look­ing to dou­ble down on its brand­ed med­i­cines with the goal of hit­ting 6% an­nu­al growth each year — pre­vi­ous­ly un­heard-of at old Pfiz­er — while con­tin­u­ing to de­vel­op its block­buster pipeline, CEO Al­bert Bourla said at a JP Mor­gan fire­side chat Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.